Cargando…

Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future

SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is among the most common cancer diseases worldwide and has only limited treatment options at advanced disease stages. Activation of the immune system with checkpoint inhibitors has revolutionized cancer medicine and has become important also for HCC tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ocker, Matthias, Mayr, Christian, Kiesslich, Tobias, Stintzing, Sebastian, Neureiter, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036419/ https://www.ncbi.nlm.nih.gov/pubmed/33805268 http://dx.doi.org/10.3390/cancers13071558

Ejemplares similares

Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
por: Neureiter, Daniel, et al.
Publicado: (2019)

Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation
por: Bekric, Dino, et al.
Publicado: (2022)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma
por: Bekric, Dino, et al.
Publicado: (2023)

Biliary tract cancer stem cells - translational options and challenges
por: Mayr, Christian, et al.
Publicado: (2017)

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
por: Ellinghaus, Peter, et al.
Publicado: (2022)

Investigating immunmodulatory mechanisms of cannabinoids: the role of MMP-9
por: Tauber, S, et al.
Publicado: (2009)

The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications
por: Klieser, Eckhard, et al.
Publicado: (2019)

The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells
por: Mayr, Christian, et al.
Publicado: (2015)

NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?
por: Kiesslich, Tobias, et al.
Publicado: (2019)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
por: Tovoli, Francesco, et al.
Publicado: (2020)

The Cancer Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell Characteristics
por: Beyreis, Marlena, et al.
Publicado: (2019)

Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers
por: Mayr, Christian, et al.
Publicado: (2016)

Influence of Five Potential Anticancer Drugs on Wnt Pathway and Cell Survival in Human Biliary Tract Cancer Cells
por: WACHTER, Julia, et al.
Publicado: (2011)

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
por: Zopf, Steffen, et al.
Publicado: (2012)

Can We Efficiently Target HDAC in Cancer?
por: Kiesslich, Tobias, et al.
Publicado: (2022)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells
por: Mayr, Christian, et al.
Publicado: (2015)

Pancreatic cancer in young adults: changes, challenges, and solutions
por: Primavesi, Florian, et al.
Publicado: (2019)

Long Non-Coding RNAs in Biliary Tract Cancer—An Up-to-Date Review
por: Bekric, Dino, et al.
Publicado: (2020)

Low VDAC1 Expression Is Associated with an Aggressive Phenotype and Reduced Overall Patient Survival in Cholangiocellular Carcinoma
por: Feichtinger, René Günther, et al.
Publicado: (2019)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
por: Mayr, Christian, et al.
Publicado: (2021)

MicroRNAs Associated with the Efficacy of Photodynamic Therapy in Biliary Tract Cancer Cell Lines
por: Wagner, Andrej, et al.
Publicado: (2014)

Miniaturization of the Clonogenic Assay Using Confluence Measurement
por: Mayr, Christian, et al.
Publicado: (2018)

Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
por: Valind, Anders, et al.
Publicado: (2021)

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
por: Di Fazio, Pietro, et al.
Publicado: (2010)

GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
por: Illig, Romana, et al.
Publicado: (2013)

Ouabain at nanomolar concentrations is cytotoxic for biliary tract cancer cells
por: Mayr, Christian, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
por: Moslehi, Javid, et al.
Publicado: (2022)

Biomarkers for hepatocellular carcinoma: What’s new on the horizon?
por: Ocker, Matthias
Publicado: (2018)

Metabolism and cancer: the future is now
por: Frezza, Christian
Publicado: (2019)

Five future strategies you need right now
por: Stalk, George, et al.
Publicado: (2008)

The Future Is Now
por: Tilson, Hugh A., et al.
Publicado: (2012)

The future is now
por: Fernandes, Frederico Leon Arrabal, et al.
Publicado: (2019)

Continuous, label-free, 96-well-based determination of cell migration using confluence measurement
por: Mayr, Christian, et al.
Publicado: (2018)

Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
por: Bekric, Dino, et al.
Publicado: (2023)

Dissecting the immune cell landscape in hepatocellular carcinoma—are we understanding complexity?
por: Ocker, Matthias
Publicado: (2020)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

The future is now: beyond first line systemic therapy in hepatocellular carcinoma
por: Nenu, Iuliana, et al.
Publicado: (2019)

HDAC-Linked “Proliferative” miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors
por: Klieser, Eckhard, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_45uh9dvm52b7isr97ab06qrffe